Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunther Hartmann

Showing results (21-30 of 199) with videos related to

Pageof 20
Sort By:
Human Immunology|December 14, 2002
Plasmacytoid dendritic cells: the key to CpGSimon Rothenfusser, Evelyn Tuma, Stefan Endres, et al.
Antiviral Therapy|October 1, 2004
Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitolEva-Jasmin Freyschmidt, Angel Alonso, Gunther Hartmann, et al.
Advances in Immunology|March 28, 2012
Nucleic acid adjuvants: toward an educated vaccineJasper G van den Boorn, Winfried Barchet, Gunther Hartmann
International Journal of Cancer|January 3, 2006
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancerCarole Bourquin, Susanne Schreiber, Sebastian Beck, et al.
Current Opinion in Molecular Therapeutics|May 30, 2003
Recent advances in immunostimulatory CpG oligonucleotidesSimon Rothenfusser, Evelyn Tuma, Moritz Wagner, et al.
Frontiers in Immunology|March 20, 2023
Increased IKKϵ protein stability ensures efficient type I interferon responses in conditions of TBK1 deficiencyJulia Wegner, Charlotte Hunkler, Katrin Ciupka, et al.
Pharmacology & Therapeutics|June 25, 2021
Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventionsMarcel Renn, Eva Bartok, Thomas Zillinger, et al.
Nature Biotechnology|April 12, 2011
SiRNA delivery with exosome nanoparticlesJasper G van den Boorn, Martin Schlee, Christoph Coch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 5, 2002
CpG oligonucleotides: novel regulators of osteoclast differentiationWei Zou, Harry Schwartz, Stefan Endres, et al.
Plos One|October 22, 2015
Where Failure Is Not an Option -Personalized Medicine in AstronautsJulia C Stingl, Susanne Welker, Gunther Hartmann, et al.
Pageof 20

Showing results (21-30 of 199) with videos related to

Sort By:
Pageof 20
Human Immunology|December 14, 2002
Plasmacytoid dendritic cells: the key to CpGSimon Rothenfusser, Evelyn Tuma, Stefan Endres, et al.
Antiviral Therapy|October 1, 2004
Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitolEva-Jasmin Freyschmidt, Angel Alonso, Gunther Hartmann, et al.
Advances in Immunology|March 28, 2012
Nucleic acid adjuvants: toward an educated vaccineJasper G van den Boorn, Winfried Barchet, Gunther Hartmann
International Journal of Cancer|January 3, 2006
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancerCarole Bourquin, Susanne Schreiber, Sebastian Beck, et al.
Current Opinion in Molecular Therapeutics|May 30, 2003
Recent advances in immunostimulatory CpG oligonucleotidesSimon Rothenfusser, Evelyn Tuma, Moritz Wagner, et al.
Frontiers in Immunology|March 20, 2023
Increased IKKϵ protein stability ensures efficient type I interferon responses in conditions of TBK1 deficiencyJulia Wegner, Charlotte Hunkler, Katrin Ciupka, et al.
Pharmacology & Therapeutics|June 25, 2021
Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventionsMarcel Renn, Eva Bartok, Thomas Zillinger, et al.
Nature Biotechnology|April 12, 2011
SiRNA delivery with exosome nanoparticlesJasper G van den Boorn, Martin Schlee, Christoph Coch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 5, 2002
CpG oligonucleotides: novel regulators of osteoclast differentiationWei Zou, Harry Schwartz, Stefan Endres, et al.
Plos One|October 22, 2015
Where Failure Is Not an Option -Personalized Medicine in AstronautsJulia C Stingl, Susanne Welker, Gunther Hartmann, et al.
Pageof 20